Skip to content
2000
  1. Home
  2. A-Z Publications
  3. Current Computer - Aided Drug Design
  4. Fast Track Articles
  5. Fast Track Article
image of HOXC-AS1: A Key Biomarker for Prognosis and Immunotherapy in Lung Adenocarcinoma

Abstract

Background

The function of HOXC antisense RNA 1 (HOXC-AS1) in lung adenocarcinoma (LUAD) remains largely unexplored.

Objective

The objective of this research was to examine the relationship between HOXC-AS1 levels and LUAD through both bioinformatics analysis and experimental validation.

Methods

We employed statistical methods and bioinformatics to evaluate the correlation between HOXC-AS1 expression and various clinical features, survival predictors, regulatory mechanisms, and immune cell infiltration in LUAD. The levels of HOXC-AS1 in LUAD cell lines were ascertained through quantitative reverse transcription PCR.

Results

HOXC-AS1 displayed significantly increased expression in individuals with LUAD. There was a significant correlation between high HOXC-AS1 levels and diminished overall survival in LUAD patients, characterized by a hazard ratio of 0.66, a 95% confidence interval of 0.49 to 0.88, and a statistically significant -value (0.005). An elevated expression of HOXC-AS1 was found to be a standalone predictor of poor overall survival in LUAD patients, with a P-value of 0.002. HOXC-AS1 was found to be implicated in various pathways, such as neuroactive ligand-receptor interaction and asthma, among others. The study revealed a substantial link between high HOXC-AS1 expression and unfavorable outcomes in LUAD, including poor survival and altered immune cell infiltration. LUAD cell lines exhibited a marked increase in HOXC-AS1 expression compared to the Beas-2B normal lung cell line.

Conclusion

The research indicated a strong association between higher levels of HOXC-AS1 and negative outcomes in LUAD, such as reduced survival rates and the presence of immune cell infiltration. HOXC-AS1 could potentially be utilized as a biomarker to anticipate patient prognosis and their likelihood of responding to immunotherapies in LUAD.

© 2025 Bentham Science Publishers
Loading

Article metrics loading...

/content/journals/cad/10.2174/0115734099353461250219072304
2025-03-06
2025-04-22

  • From This Site

    /content/journals/cad/10.2174/0115734099353461250219072304
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

References

  1. Sung H. Ferlay J. Siegel R.L. Laversanne M. Soerjomataram I. Jemal A. Bray F. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 Countries. CA Cancer J. Clin. 2021 71 3 209 249 10.3322/caac.21660 33538338
    [Google Scholar]
  2. Chiang H.H. Ong C.T. Chang C.Y. Wu K.L. Wu Y.Y. Lai J.C. Shen T.Y. Hung J.Y. Lee H.C. Tsai Y.M. Hsu Y.L. Downregulated antisense lncRNA ENTPD3-AS1 contributes to the development of lung adenocarcinoma. Am. J. Cancer Res. 2024 14 2 854 868 10.62347/THCL6758 38455397
    [Google Scholar]
  3. Denisenko T.V. Budkevich I.N. Zhivotovsky B. Cell death-based treatment of lung adenocarcinoma. Cell Death Dis. 2018 9 2 117 10.1038/s41419‑017‑0063‑y 29371589
    [Google Scholar]
  4. de Groot P.M. Wu C.C. Carter B.W. Munden R.F. The epidemiology of lung cancer. Transl. Lung Cancer Res. 2018 7 3 220 233 10.21037/tlcr.2018.05.06 30050761
    [Google Scholar]
  5. Wang J. Li J. LncRNA MIR155HG functions as a ceRNA for inhibition of lung adenocarcinoma growth and prediction of prognosis. Arch. Med. Sci. 2021 20 2 539 556 10.5114/aoms/161285 38757039
    [Google Scholar]
  6. Arnold BN Thomas DC Rosen JE Salazar MC Blasberg JD Boffa DJ Detterbeck M.C. Lung cancer in the very young: Treatment and survival in the national cancer data base. J. Thorac Oncol. 2016 11 7 1121 10.1016/j.jtho.2016.03.023.
    [Google Scholar]
  7. Carnio S. Di Stefano R. Novello S. Fatigue in lung cancer patients: Symptom burden and management of challenges. Lung Cancer (Auckl.) 2016 7 73 82 10.2147/LCTT.S85334 28210163
    [Google Scholar]
  8. Yousem S.A. Role of molecular studies in the diagnosis of lung adenocarcinoma. Mod Pathol. 2012 25 Suppl. 1 S11 S17
    [Google Scholar]
  9. Cooke M. Baker M.J. Kazanietz M.G. Rac-GEF/Rac signaling and metastatic dissemination in lung cancer. Front. Cell Dev. Biol. 2020 8 118 10.3389/fcell.2020.00118 32158759
    [Google Scholar]
  10. Richardson A.M. Havel L.S. Koyen A.E. Konen J.M. Shupe J. Wiles W.G. IV Martin W.D. Grossniklaus H.E. Sica G. Gilbert-Ross M. Marcus A.I. Vimentin is required for lung adenocarcinoma metastasis via heterotypic tumor cell–cancer-associated fibroblast interactions during collective invasion. Clin. Cancer Res. 2018 24 2 420 432 10.1158/1078‑0432.CCR‑17‑1776 29208669
    [Google Scholar]
  11. Jarroux J. Morillon A. Pinskaya M. History, discovery, and classification of lncRNAs. Adv. Exp. Med. Biol. 2017 1008 1 46 10.1007/978‑981‑10‑5203‑3_1 28815535
    [Google Scholar]
  12. Zhao W. Qin P. Zhang D. Cui X. Gao J. Yu Z. Chai Y. Wang J. Li J. Long non-coding RNA PVT1 encapsulated in bone marrow mesenchymal stem cell-derived exosomes promotes osteosarcoma growth and metastasis by stabilizing ERG and sponging miR-183-5p. Aging (Albany NY) 2019 11 21 9581 9596 10.18632/aging.102406 31699956
    [Google Scholar]
  13. Bolha L. Ravnik-Glavač M. Glavač D. Long noncoding RNAs as biomarkers in cancer. Dis. Markers 2017 2017 1 14 10.1155/2017/7243968 28634418
    [Google Scholar]
  14. Wang X. Li L. Zhao K. Lin Q. Li H. Xue X. Ge W. He H. Liu D. Xie H. Wu Q. Hu Y. A novel LncRNA HITT forms a regulatory loop with HIF-1α to modulate angiogenesis and tumor growth. Cell Death Differ. 2020 27 4 1431 1446 10.1038/s41418‑019‑0449‑8 31700144
    [Google Scholar]
  15. Zhou H.J. Wang L.Q. Wang D.B. Yu J.B. Zhu Y. Xu Q.S. Zheng X.J. Zhan R.Y. Long noncoding RNA MALAT1 contributes to inflammatory response of microglia following spinal cord injury via the modulation of a miR-199b/IKKβ/NF-κB signaling pathway. Am. J. Physiol. Cell Physiol. 2018 315 1 C52 C61 10.1152/ajpcell.00278.2017 29631367
    [Google Scholar]
  16. Deng X. Xiong W. Jiang X. Zhang S. Li Z. Zhou Y. Xiang B. Zhou M. Li X. Li G. Zeng Z. Gong Z. LncRNA LINC00472 regulates cell stiffness and inhibits the migration and invasion of lung adenocarcinoma by binding to YBX1. Cell Death Dis. 2020 11 11 945 10.1038/s41419‑020‑03147‑9 33144579
    [Google Scholar]
  17. Dong H.X. Wang R. Jin X.Y. Zeng J. Pan J. LncRNA DGCR5 promotes lung adenocarcinoma (LUAD) progression via inhibiting hsa‐mir‐22‐3p. J. Cell. Physiol. 2018 233 5 4126 4136 10.1002/jcp.26215 29030962
    [Google Scholar]
  18. Zhao M. Xin X.F. Zhang J.Y. Dai W. Lv T.F. Song Y. LncRNA GMDS‐AS1 inhibits lung adenocarcinoma development by regulating miR‐96‐5p/CYLD signaling. Cancer Med. 2020 9 3 1196 1208 10.1002/cam4.2776 31860169
    [Google Scholar]
  19. Yang Z. Wan J. Ma L. Li Z. Yang R. Yang H. Li J. Zhou F. Ming L. Long non‐coding RNA HOXC‐AS1 exerts its oncogenic effects in esophageal squamous cell carcinoma by interaction with IGF2BP2 to stabilize SIRT1 expression. J. Clin. Lab. Anal. 2023 37 1 e24801 10.1002/jcla.24801 36510377
    [Google Scholar]
  20. Jiang Y. Li X. Yang Y. Luo J. Ren X. Yuan J. Tong Q. LncRNA HOXC-AS1 sponges miR-99a-3p and upregulates MMP8, ultimately promoting gastric cancer. Cancers 2022 14 14 3534 10.3390/cancers14143534 35884594
    [Google Scholar]
  21. Zhou C. An N. Cao C. Wang G. lncRNA HOXC‐AS1 promotes gastric cancer via binding eIF4AIII by activating Wnt/β‐catenin signaling. J. Gene Med. 2020 22 9 e3202 10.1002/jgm.3202 32307743
    [Google Scholar]
  22. Dong Y. Li X. Lin Z. Zou W. Liu Y. Qian H. HOXC-AS1-MYC regulatory loop contributes to the growth and metastasis in gastric cancer. J. Exp. Clin. Cancer Res. 2019 38 1 502
    [Google Scholar]
  23. Tang Z. Zeng X. Li J. Qiu S. Zhao H. Wang Z. Zheng Y. LncRNA HOXC-AS1 promotes nasopharyngeal carcinoma (NPC) progression by sponging miR-4651 and subsequently upregulating FOXO6. J. Pharmacol. Sci. 2021 147 3 284 293 10.1016/j.jphs.2021.08.002 34507637
    [Google Scholar]
  24. Ren L. Pan X. Ning L. Gong D. Huang J. Deng K. Xie L. Zhang Y. Construction of a combined hypoxia-related genes model for hepatocellular carcinoma prognosis. Curr. Computeraided Drug Des. 2023 19 2 150 161 10.2174/1573409919666221223123610 36567292
    [Google Scholar]
  25. Zhong Y. Pan S. Zhi S. Li Y. Xiu Z. Wei C. Luo J. Construction and investigation of circRNA-associated ceRNA regulatory network in molecular subtypes of breast cancer. Curr. Computeraided Drug Des. 2022 18 3 185 195 35708093
    [Google Scholar]
  26. Liu J. Lichtenberg T. Hoadley K.A. Poisson L.M. Lazar A.J. Cherniack A.D. Kovatich A.J. Benz C.C. Levine D.A. Lee A.V. Omberg L. Wolf D.M. Shriver C.D. Thorsson V. Hu H. Caesar-Johnson S.J. Demchok J.A. Felau I. Kasapi M. Ferguson M.L. Hutter C.M. Sofia H.J. Tarnuzzer R. Wang Z. Yang L. Zenklusen J.C. Zhang J.J. Chudamani S. Liu J. Lolla L. Naresh R. Pihl T. Sun Q. Wan Y. Wu Y. Cho J. DeFreitas T. Frazer S. Gehlenborg N. Getz G. Heiman D.I. Kim J. Lawrence M.S. Lin P. Meier S. Noble M.S. Saksena G. Voet D. Zhang H. Bernard B. Chambwe N. Dhankani V. Knijnenburg T. Kramer R. Leinonen K. Liu Y. Miller M. Reynolds S. Shmulevich I. Thorsson V. Zhang W. Akbani R. Broom B.M. Hegde A.M. Ju Z. Kanchi R.S. Korkut A. Li J. Liang H. Ling S. Liu W. Lu Y. Mills G.B. Ng K-S. Rao A. Ryan M. Wang J. Weinstein J.N. Zhang J. Abeshouse A. Armenia J. Chakravarty D. Chatila W.K. de Bruijn I. Gao J. Gross B.E. Heins Z.J. Kundra R. La K. Ladanyi M. Luna A. Nissan M.G. Ochoa A. Phillips S.M. Reznik E. Sanchez-Vega F. Sander C. Schultz N. Sheridan R. Sumer S.O. Sun Y. Taylor B.S. Wang J. Zhang H. Anur P. Peto M. Spellman P. Benz C. Stuart J.M. Wong C.K. Yau C. Hayes D.N. Parker J.S. Wilkerson M.D. Ally A. Balasundaram M. Bowlby R. Brooks D. Carlsen R. Chuah E. Dhalla N. Holt R. Jones S.J.M. Kasaian K. Lee D. Ma Y. Marra M.A. Mayo M. Moore R.A. Mungall A.J. Mungall K. Robertson A.G. Sadeghi S. Schein J.E. Sipahimalani P. Tam A. Thiessen N. Tse K. Wong T. Berger A.C. Beroukhim R. Cherniack A.D. Cibulskis C. Gabriel S.B. Gao G.F. Ha G. Meyerson M. Schumacher S.E. Shih J. Kucherlapati M.H. Kucherlapati R.S. Baylin S. Cope L. Danilova L. Bootwalla M.S. Lai P.H. Maglinte D.T. Van Den Berg D.J. Weisenberger D.J. Auman J.T. Balu S. Bodenheimer T. Fan C. Hoadley K.A. Hoyle A.P. Jefferys S.R. Jones C.D. Meng S. Mieczkowski P.A. Mose L.E. Perou A.H. Perou C.M. Roach J. Shi Y. Simons J.V. Skelly T. Soloway M.G. Tan D. Veluvolu U. Fan H. Hinoue T. Laird P.W. Shen H. Zhou W. Bellair M. Chang K. Covington K. Creighton C.J. Dinh H. Doddapaneni H.V. Donehower L.A. Drummond J. Gibbs R.A. Glenn R. Hale W. Han Y. Hu J. Korchina V. Lee S. Lewis L. Li W. Liu X. Morgan M. Morton D. Muzny D. Santibanez J. Sheth M. Shinbro E. Wang L. Wang M. Wheeler D.A. Xi L. Zhao F. Hess J. Appelbaum E.L. Bailey M. Cordes M.G. Ding L. Fronick C.C. Fulton L.A. Fulton R.S. Kandoth C. Mardis E.R. McLellan M.D. Miller C.A. Schmidt H.K. Wilson R.K. Crain D. Curley E. Gardner J. Lau K. Mallery D. Morris S. Paulauskis J. Penny R. Shelton C. Shelton T. Sherman M. Thompson E. Yena P. Bowen J. Gastier-Foster J.M. Gerken M. Leraas K.M. Lichtenberg T.M. Ramirez N.C. Wise L. Zmuda E. Corcoran N. Costello T. Hovens C. Carvalho A.L. de Carvalho A.C. Fregnani J.H. Longatto-Filho A. Reis R.M. Scapulatempo-Neto C. Silveira H.C.S. Vidal D.O. Burnette A. Eschbacher J. Hermes B. Noss A. Singh R. Anderson M.L. Castro P.D. Ittmann M. Huntsman D. Kohl B. Le X. Thorp R. Andry C. Duffy E.R. Lyadov V. Paklina O. Setdikova G. Shabunin A. Tavobilov M. McPherson C. Warnick R. Berkowitz R. Cramer D. Feltmate C. Horowitz N. Kibel A. Muto M. Raut C.P. Malykh A. Barnholtz-Sloan J.S. Barrett W. Devine K. Fulop J. Ostrom Q.T. Shimmel K. Wolinsky Y. Sloan A.E. De Rose A. Giuliante F. Goodman M. Karlan B.Y. Hagedorn C.H. Eckman J. Harr J. Myers J. Tucker K. Zach L.A. Deyarmin B. Hu H. Kvecher L. Larson C. Mural R.J. Somiari S. Vicha A. Zelinka T. Bennett J. Iacocca M. Rabeno B. Swanson P. Latour M. Lacombe L. Têtu B. Bergeron A. McGraw M. Staugaitis S.M. Chabot J. Hibshoosh H. Sepulveda A. Su T. Wang T. Potapova O. Voronina O. Desjardins L. Mariani O. Roman-Roman S. Sastre X. Stern M-H. Cheng F. Signoretti S. Berchuck A. Bigner D. Lipp E. Marks J. McCall S. McLendon R. Secord A. Sharp A. Behera M. Brat D.J. Chen A. Delman K. Force S. Khuri F. Magliocca K. Maithel S. Olson J.J. Owonikoko T. Pickens A. Ramalingam S. Shin D.M. Sica G. Van Meir E.G. Zhang H. Eijckenboom W. Gillis A. Korpershoek E. Looijenga L. Oosterhuis W. Stoop H. van Kessel K.E. Zwarthoff E.C. Calatozzolo C. Cuppini L. Cuzzubbo S. DiMeco F. Finocchiaro G. Mattei L. Perin A. Pollo B. Chen C. Houck J. Lohavanichbutr P. Hartmann A. Stoehr C. Stoehr R. Taubert H. Wach S. Wullich B. Kycler W. Murawa D. Wiznerowicz M. Chung K. Edenfield W.J. Martin J. Baudin E. Bubley G. Bueno R. De Rienzo A. Richards W.G. Kalkanis S. Mikkelsen T. Noushmehr H. Scarpace L. Girard N. Aymerich M. Campo E. Giné E. Guillermo A.L. Van Bang N. Hanh P.T. Phu B.D. Tang Y. Colman H. Evason K. Dottino P.R. Martignetti J.A. Gabra H. Juhl H. Akeredolu T. Stepa S. Hoon D. Ahn K. Kang K.J. Beuschlein F. Breggia A. Birrer M. Bell D. Borad M. Bryce A.H. Castle E. Chandan V. Cheville J. Copland J.A. Farnell M. Flotte T. Giama N. Ho T. Kendrick M. Kocher J-P. Kopp K. Moser C. Nagorney D. O’Brien D. O’Neill B.P. Patel T. Petersen G. Que F. Rivera M. Roberts L. Smallridge R. Smyrk T. Stanton M. Thompson R.H. Torbenson M. Yang J.D. Zhang L. Brimo F. Ajani J.A. Angulo Gonzalez A.M. Behrens C. Bondaruk J. Broaddus R. Czerniak B. Esmaeli B. Fujimoto J. Gershenwald J. Guo C. Lazar A.J. Logothetis C. Meric-Bernstam F. Moran C. Ramondetta L. Rice D. Sood A. Tamboli P. Thompson T. Troncoso P. Tsao A. Wistuba I. Carter C. Haydu L. Hersey P. Jakrot V. Kakavand H. Kefford R. Lee K. Long G. Mann G. Quinn M. Saw R. Scolyer R. Shannon K. Spillane A. Stretch J. Synott M. Thompson J. Wilmott J. Al-Ahmadie H. Chan T.A. Ghossein R. Gopalan A. Levine D.A. Reuter V. Singer S. Singh B. Tien N.V. Broudy T. Mirsaidi C. Nair P. Drwiega P. Miller J. Smith J. Zaren H. Park J-W. Hung N.P. Kebebew E. Linehan W.M. Metwalli A.R. Pacak K. Pinto P.A. Schiffman M. Schmidt L.S. Vocke C.D. Wentzensen N. Worrell R. Yang H. Moncrieff M. Goparaju C. Melamed J. Pass H. Botnariuc N. Caraman I. Cernat M. Chemencedji I. Clipca A. Doruc S. Gorincioi G. Mura S. Pirtac M. Stancul I. Tcaciuc D. Albert M. Alexopoulou I. Arnaout A. Bartlett J. Engel J. Gilbert S. Parfitt J. Sekhon H. Thomas G. Rassl D.M. Rintoul R.C. Bifulco C. Tamakawa R. Urba W. Hayward N. Timmers H. Antenucci A. Facciolo F. Grazi G. Marino M. Merola R. de Krijger R. Gimenez-Roqueplo A-P. Piché A. Chevalier S. McKercher G. Birsoy K. Barnett G. Brewer C. Farver C. Naska T. Pennell N.A. Raymond D. Schilero C. Smolenski K. Williams F. Morrison C. Borgia J.A. Liptay M.J. Pool M. Seder C.W. Junker K. Omberg L. Dinkin M. Manikhas G. Alvaro D. Bragazzi M.C. Cardinale V. Carpino G. Gaudio E. Chesla D. Cottingham S. Dubina M. Moiseenko F. Dhanasekaran R. Becker K-F. Janssen K-P. Slotta-Huspenina J. Abdel-Rahman M.H. Aziz D. Bell S. Cebulla C.M. Davis A. Duell R. Elder J.B. Hilty J. Kumar B. Lang J. Lehman N.L. Mandt R. Nguyen P. Pilarski R. Rai K. Schoenfield L. Senecal K. Wakely P. Hansen P. Lechan R. Powers J. Tischler A. Grizzle W.E. Sexton K.C. Kastl A. Henderson J. Porten S. Waldmann J. Fassnacht M. Asa S.L. Schadendorf D. Couce M. Graefen M. Huland H. Sauter G. Schlomm T. Simon R. Tennstedt P. Olabode O. Nelson M. Bathe O. Carroll P.R. Chan J.M. Disaia P. Glenn P. Kelley R.K. Landen C.N. Phillips J. Prados M. Simko J. Smith-McCune K. VandenBerg S. Roggin K. Fehrenbach A. Kendler A. Sifri S. Steele R. Jimeno A. Carey F. Forgie I. Mannelli M. Carney M. Hernandez B. Campos B. Herold-Mende C. Jungk C. Unterberg A. von Deimling A. Bossler A. Galbraith J. Jacobus L. Knudson M. Knutson T. Ma D. Milhem M. Sigmund R. Godwin A.K. Madan R. Rosenthal H.G. Adebamowo C. Adebamowo S.N. Boussioutas A. Beer D. Giordano T. Mes-Masson A-M. Saad F. Bocklage T. Landrum L. Mannel R. Moore K. Moxley K. Postier R. Walker J. Zuna R. Feldman M. Valdivieso F. Dhir R. Luketich J. Mora Pinero E.M. Quintero-Aguilo M. Carlotti C.G. Jr Dos Santos J.S. Kemp R. Sankarankuty A. Tirapelli D. Catto J. Agnew K. Swisher E. Creaney J. Robinson B. Shelley C.S. Godwin E.M. Kendall S. Shipman C. Bradford C. Carey T. Haddad A. Moyer J. Peterson L. Prince M. Rozek L. Wolf G. Bowman R. Fong K.M. Yang I. Korst R. Rathmell W.K. Fantacone-Campbell J.L. Hooke J.A. Kovatich A.J. Shriver C.D. DiPersio J. Drake B. Govindan R. Heath S. Ley T. Van Tine B. Westervelt P. Rubin M.A. Lee J.I. Aredes N.D. Mariamidze A. Cancer Genome Atlas Research Network An integrated TCGA Pan-cancer clinical data resource to drive high-quality survival outcome analytics. Cell 2018 173 2 400 416.e11 10.1016/j.cell.2018.02.052 29625055
    [Google Scholar]
  27. Wei Y. Liu C. Network pharmacology combined with GEO analysis of the mechanism of Qing-Jin-Hua-Tan decoction in the treatment of non-small cell lung cancer. Curr. Computeraided Drug Des. 2024 20 4 396 404 10.2174/1573409919666230523155830 37231755
    [Google Scholar]
  28. Hänzelmann S. Castelo R. Guinney J. GSVA: Gene set variation analysis for microarray and RNA-Seq data. BMC Bioinformatics 2013 14 1 7 10.1186/1471‑2105‑14‑7 23323831
    [Google Scholar]
  29. Bindea G. Mlecnik B. Tosolini M. Kirilovsky A. Waldner M. Obenauf A.C. Angell H. Fredriksen T. Lafontaine L. Berger A. Bruneval P. Fridman W.H. Becker C. Pagès F. Speicher M.R. Trajanoski Z. Galon J. Spatiotemporal dynamics of intratumoral immune cells reveal the immune landscape in human cancer. Immunity 2013 39 4 782 795 10.1016/j.immuni.2013.10.003 24138885
    [Google Scholar]
  30. Yoshihara K. Shahmoradgoli M. Martínez E. Vegesna R. Kim H. Torres-Garcia W. Treviño V. Shen H. Laird P.W. Levine D.A. Carter S.L. Getz G. Stemke-Hale K. Mills G.B. Verhaak R.G.W. Inferring tumour purity and stromal and immune cell admixture from expression data. Nat. Commun. 2013 4 1 2612 10.1038/ncomms3612 24113773
    [Google Scholar]
  31. Liang W. Lu Y. Pan X. Zeng Y. Zheng W. Li Y. Nie Y. Li D. Wang D. Decreased expression of a novel lncRNA FAM181A-AS1 is associated with poor prognosis and immune infiltration in lung adenocarcinoma. Pharm. Genomics Pers. Med. 2022 15 985 998 10.2147/PGPM.S384901 36482943
    [Google Scholar]
  32. He H. Yuan F. Li Y. Pi G. Shi H. Li Y. Han G. Comprehensive analysis and experimental validation of FOXD2 as a novel potential prognostic biomarker associated with immune infiltration in head and neck squamous cell carcinoma. Curr. Computeraided Drug Des. 2024 20 10.2174/0115734099302492240405065505 38629358
    [Google Scholar]
  33. Jiang X. Chen X. Guo J. Zhou F. Pu J. Mutti L. Niu X. Identification and validation of lncRNA-AC087588.2 in lung adenocarcinoma: A novel prognostic and diagnostic indicator. Front. Mol. Biosci. 2022 9 923584 10.3389/fmolb.2022.923584 35769906
    [Google Scholar]
  34. Chen X. Guo J. Zhou F. Ren W. Pu J. Mutti L. Niu X. Jiang X. Over-expression of long non-coding RNA-AC099850.3 correlates with tumor progression and poor prognosis in lung adenocarcinoma. Front. Oncol. 2022 12 895708 10.3389/fonc.2022.895708 35646670
    [Google Scholar]
  35. He Y Luan X Lin Y Dong C Zhang J Zhu Y. lncRNA AGAP11 suppresses lung adenocarcinoma progression by miR-494-3p and predicts prognosis. J. Environ Pathol Toxicol Oncol. 2024 43 4 1 11 10.1615/JEnvironPatholToxicolOncol.
    [Google Scholar]
  36. Jiang X. Chen M. Du J. Bi H. Guo X. Yang C. He X. Jin Z. LncRNA-AC068228.1 Is a novel prognostic biomarker that promotes malignant phenotypes in lung adenocarcinoma. Front. Oncol. 2022 12 856655 10.3389/fonc.2022.856655 35280807
    [Google Scholar]
  37. Chen Z. Yang X. Bi G. Liang J. Hu Z. Zhao M. Li M. Lu T. Zheng Y. Sui Q. Yang Y. Zhan C. Jiang W. Wang Q. Tan L. Ligand-receptor interaction atlas within and between tumor cells and T cells in lung adenocarcinoma. Int. J. Biol. Sci. 2020 16 12 2205 2219 10.7150/ijbs.42080 32549766
    [Google Scholar]
  38. Peng H. Li C. Wu X. Wen Y. Lin J. Liang H. Zhong R. Liu J. He J. Liang W. Association between systemic lupus erythematosus and lung cancer: results from a pool of cohort studies and Mendelian randomization analysis. J. Thorac. Dis. 2020 12 10 5299 5312 10.21037/jtd‑20‑2462 33209364
    [Google Scholar]
  39. Madama D. Martins R. Pires A.S. Botelho M.F. Alves M.G. Abrantes A.M. Cordeiro C.R. Metabolomic profiling in lung cancer: A systematic review. Metabolites 2021 11 9 630 10.3390/metabo11090630 34564447
    [Google Scholar]
  40. Nishida K. Tojo T. Kondo T. Yuasa M. Evaluation of the correlation between porphyrin accumulation in cancer cells and functional positions for application as a drug carrier. Sci. Rep. 2021 11 1 2046 10.1038/s41598‑021‑81725‑3 33479459
    [Google Scholar]
  41. Mahata B. Pramanik J. van der Weyden L. Polanski K. Kar G. Riedel A. Chen X. Fonseca N.A. Kundu K. Campos L.S. Ryder E. Duddy G. Walczak I. Okkenhaug K. Adams D.J. Shields J.D. Teichmann S.A. Tumors induce de novo steroid biosynthesis in T cells to evade immunity. Nat. Commun. 2020 11 1 3588 10.1038/s41467‑020‑17339‑6 32680985
    [Google Scholar]
  42. Rosario S.R. Long M.D. Affronti H.C. Rowsam A.M. Eng K.H. Smiraglia D.J. Pan-cancer analysis of transcriptional metabolic dysregulation using The Cancer Genome Atlas. Nat. Commun. 2018 9 1 5330 10.1038/s41467‑018‑07232‑8 30552315
    [Google Scholar]
  43. Qu Y.L. Liu J. Zhang L.X. Wu C.M. Chu A.J. Wen B.L. Ma C. Yan X. Zhang X. Wang D.M. Lv X. Hou S.J. Asthma and the risk of lung cancer: A meta-analysis. Oncotarget 2017 8 7 11614 11620 10.18632/oncotarget.14595 28086224
    [Google Scholar]
/content/journals/cad/10.2174/0115734099353461250219072304
Loading
HOXC-AS1: A Key Biomarker for Prognosis and Immunotherapy in Lung Adenocarcinoma
Bentham Science Publishers ; https://doi.org/10.2174/0115734099353461250219072304
/content/journals/cad/10.2174/0115734099353461250219072304
/content/journals/cad/10.2174/0115734099353461250219072304
Loading

Data & Media loading...

Supplements

Supplementary material is available on the publisher's website along with the published article.

file format download Download

  • Article Type:     Research Article
Keywords: prognosis ; lung adenocarcinoma ; neuroactive ligand-receptor interaction ; immune infiltration ; HOXC-AS1 ; biomarker

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test